External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Equity Bottom-Up

Anebulo Pharmaceuticals  / Equity Bottom-Up

Key points (machine generated)<ul><li>Anebulo Pharmaceuticals plans a significant reverse stock split to cash out small shareholders at $3.50 per share.</li><li>The reverse split aims to reduce record holders below 300, avoiding SEC reporting and saving $1.3 million annually.</li><li>The author, currently shorting the stock, warns of the $1.8 million costs of the transaction and advises independent research.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Anebulo Pharmaceuticals plans a significant reverse stock split to cash out small shareholders at $3.50 per share.The reverse split aims to reduce record holders below 300, avoiding SEC reporting and saving $1.3 million annually.The author, currently shorting the stock, warns of the $1.8 million costs of the transaction and advises independent research.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Anebulo Pharma Inc (ANEB) - Wednesday, Jul 23, 2025

United States

Anebulo Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing disruptive treatments for substance use disorders, such as cannabinoid overdose and the broader addiction landscape. Anebulo Pharmaceuticals serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Anebulo Pharmaceuticals (ANEB US)

Anebulo Pharma Inc (ANEB) - Wednesday, Jul 23, 2025

The author warns about Anebulo Pharmaceuticals' planned reverse stock split to reduce shareholders and avoid SEC costs, highlighting financial...

Value Investors Club (VIC)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)